HEMATOLOGICAL MALIGNANCIES

This study follows patients who received Galapagos CAR T-cell therapies for blood cancers to monitor their health for 15 years after treatment. Researchers want to understand the long-term safety of these therapies and track whether the modified cells remain in the body. The stud…

This is a first-in-human study to test the safety and find the right dose of a new oral drug called ICP-248. It will be given alone or combined with another drug to adults with certain advanced B-cell blood cancers that have come back or stopped responding to other treatments. Th…

This study is for older adults getting a stem cell transplant for blood cancers. It compares two different doses of a key drug (cyclophosphamide) used to prevent a serious complication called graft-versus-host disease (GVHD). The main goal is to see if a lower dose helps patients…

This study is testing a new drug called talquetamab for people with multiple myeloma, a type of blood cancer, that has returned or is no longer responding to other treatments. The main goals are to see if the drug is effective at controlling the cancer and to check how safe it is…

This is the first study in people for an experimental oral drug called HMPL-506. Its main goals are to find a safe dose and see how the body processes the drug in adults with advanced blood cancers that have returned or not responded to prior treatments. The study will also look …

This is the first human trial testing an experimental drug called DS3790a for people with various blood cancers. The study aims to find safe doses and see if the drug, given alone or with other treatments, can help control these cancers. Researchers will enroll 420 adults with bl…

This study is testing a new program where nurses start conversations about palliative care early in a child's cancer treatment. It aims to see if these regular talks improve the child's quality of life, manage symptoms better, and reduce stress for family caregivers compared to s…

This study aims to understand why some early, non-symptomatic blood conditions turn into cancer. Researchers will observe 10,000 adults who have these early conditions or a history of cancer. They will analyze genetic material from routine blood and tissue samples to identify cha…